April 10, 2023, the IND application of innovative drug LP-005 was accepted by the CDE (centre for drug evaluation, NMPA) , and the application number is CXSL2300241. LP-005 is the first complementary drug of Longbio to receive an IND application acceptance from CDE, and will also be the company's third clinical stage drug. Longbio will continue to implement the company's dual drive strategy of "allergy and complement".
Complements are the main natural immune system in the human body, and their main physiological functions include combating pathogenic microorganisms, clearing mutated or necrotic cells in the body, and regulating acquired immunity. Abnormal complement regulation is the main pathological basis or driving factor of many human diseases.
LP-005 is the first complement bifunctional antibody developed by Longbio. It is developed based on the iCibitorTM technology platform. It is intended to be used for the treatment of a variety of complement related rare disease and common diseases.
Unlike most complement drugs worldwide, LP-005 can simultaneously act on two targets of the complement system, which has the potential to achieve better therapeutic effects than single target blocking in some diseases. On the other hand, LP-005 has blocking effects on more than one pathway of complement system, which also makes it have the potential to expand more indications than single target competitors.
The IND of LP-005 is the first step for the complement technology platform iCibitorTM of Longbio. In the future, the company will lay out and develop more drugs around the complement field based on a deep understanding of the complement field and the differentiated technology platforms.
In China for Global, Longbio will continue to strive for the goal of becoming a globally leading Chinese biotech company in allergy and complement.
2023.04.11
